Recent executive moves in the industry include C-suite changes at Fresh Tracks Therapeutics and Protara Therapeutics. Meanwhile, new directors were appointed at Grey Wolf Therapeutics and BioSenic.

Novartis’s multiple sclerosis treatment Kesimpta has shot out of the gates and bidding fair to contribute generously to the firm’s coffers, while new cholesterol drug Leqvio struggles, Q1 results show.

AstraZeneca’s PD-L1/CTLA-4 combination could soon be rivalling Roche’s regimen, and may offer greater safety and tolerability for liver cancer patients.

AstraZeneca has presented more promising data from the PROVENT trial of its antibody combination therapy Evusheld which shows high levels of protection from COVID-19 for at least six months.

The Swiss biotech has raised an impressive series A round which will go towards the development of T-cell engagers based on its unique technology, with an eye to reducing off-tumor activity.

David Denton will join Pfizer from the hardware store chain Lowe’s, though he does have prior health care experience working at CVS Health.

Tapping into Abingworth’s pioneering clinical co-development model, the private equity behemoth is using that experience to form Launch Therapeutics which will seek to partner with biotech and biopharma on “best‐in‐class, late‐stage clinical assets [and] bring life‐saving therapies to market better, faster and cheaper.”